Huo Junyu, Cai Jinzhen, Guan Ge, Liu Huan, Wu Liqun
Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Front Cell Dev Biol. 2021 Nov 15;9:761839. doi: 10.3389/fcell.2021.761839. eCollection 2021.
Due to the heterogeneity of tumors and the complexity of the immune microenvironment, the specific role of ferroptosis and pyroptosis in hepatocellular carcinoma (HCC) is not fully understood, especially its impact on prognosis. The training set ( = 609, merged by TCGA and GSE14520) was clustered into three subtypes (C1, C2, and C3) based on the prognosis-related genes associated with ferroptosis and pyroptosis. The intersecting differentially expressed genes (DEGs) among C1, C2, and C3 were used in univariate Cox and LASSO penalized Cox regression analysis for the construction of the risk score. The median risk score served as the unified cutoff to divide patients into high- and low-risk groups. Internal (TCGA, = 370; GSE14520, = 239) and external validation (ICGC, = 231) suggested that the 12-gene risk score had high accuracy in predicting the OS, DSS, DFS, PFS, and RFS of HCC. As an independent prognostic indicator, the risk score could be applicable for patients with different clinical features tested by subgroup ( = 26) survival analysis. In the high-risk patients with a lower infiltration abundance of activated B cells, activated CD8 T cells, eosinophils, and type I T helper cells and a higher infiltration abundance of immature dendritic cells, the cytolytic activity, HLA, inflammation promotion, and type I IFN response in the high-risk group were weaker. The TP53 mutation rate, TMB, and CSC characteristics in the high-risk group were significantly higher than those in the low-risk group. Low-risk patients have active metabolic activity and a more robust immune response. The high- and low-risk groups differed significantly in histology grade, vascular tumor cell type, AFP, new tumor event after initial treatment, main tumor size, cirrhosis, TNM stage, BCLC stage, and CLIP score. The ferroptosis and pyroptosis molecular subtype-related signature identified and validated in this work is applicable for prognosis prediction, immune microenvironment estimation, stem cell characteristics, and clinical feature assessment in HCC.
由于肿瘤的异质性和免疫微环境的复杂性,铁死亡和焦亡在肝细胞癌(HCC)中的具体作用尚未完全明确,尤其是其对预后的影响。基于与铁死亡和焦亡相关的预后相关基因,将训练集(n = 609,由TCGA和GSE14520合并而成)聚类为三个亚型(C1、C2和C3)。使用C1、C2和C3之间的交集差异表达基因(DEG)进行单变量Cox和LASSO惩罚Cox回归分析,以构建风险评分。将中位风险评分作为统一的临界值,将患者分为高风险组和低风险组。内部验证(TCGA,n = 370;GSE14520,n = 239)和外部验证(ICGC,n = 231)表明,12基因风险评分在预测HCC的总生存期(OS)、疾病特异性生存期(DSS)、无病生存期(DFS)、无进展生存期(PFS)和复发无进展生存期(RFS)方面具有较高的准确性。作为一个独立的预后指标,该风险评分可通过亚组(n = 26)生存分析应用于具有不同临床特征的患者。在活化B细胞、活化CD8 T细胞、嗜酸性粒细胞和I型辅助性T细胞浸润丰度较低且未成熟树突状细胞浸润丰度较高的高风险患者中,高风险组的细胞溶解活性、人类白细胞抗原(HLA)、炎症促进和I型干扰素反应较弱。高风险组的TP53突变率、肿瘤突变负荷(TMB)和癌症干细胞(CSC)特征显著高于低风险组。低风险患者具有活跃的代谢活性和更强的免疫反应。高风险组和低风险组在组织学分级、血管肿瘤细胞类型、甲胎蛋白(AFP)、初始治疗后的新肿瘤事件、主要肿瘤大小、肝硬化、肿瘤-淋巴结-转移(TNM)分期、巴塞罗那临床肝癌(BCLC)分期和意大利肝癌协作组(CLIP)评分方面存在显著差异。在本研究中鉴定和验证的铁死亡和焦亡分子亚型相关特征适用于HCC的预后预测、免疫微环境评估、干细胞特征和临床特征评估。